Molecular and cellular dissection of NMDA receptor subtypes as antidepressant 
targets

Lang, Elisabeth; Mallien, Anne S.; Vasilescu, Andrei-Nicolae; Hefter, Dimitri; Luoni, Alessia; Riva, Marco A.; Borgwardt, Stefan; Sprengel, Rolf; Lang, Undine E.; Gass, Peter; Inta, Dragos

doi:10.1016/j.neubiorev.2017.08.012

Item

ITEM ACTIONSEXPORT

Add to Basket

Please note that a newer version of this item is available:
https://pure.mpg.de/pubman/item/item_2475062_3

DetailsSummary

Released

Journal Article

Molecular and cellular dissection of NMDA receptor subtypes as antidepressant targets

MPS-Authors

/persons/resource/persons95439

Sprengel, Rolf
Department of Molecular Neurobiology, Max Planck Institute for Medical Research, Max Planck Society;

External Resource

http://www.sciencedirect.com/science/article/pii/S0149763417303226/pdfft?md5=2481dbba45fc4c5c1b7f34d8707463cd&pid=1-s2.0-S0149763417303226-main.pdf
(Any fulltext)

https://doi.org/10.1016/j.neubiorev.2017.08.012
(Any fulltext)

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Lang, E., Mallien, A. S., Vasilescu, A.-N., Hefter, D., Luoni, A., Riva, M. A., et al. (2017). Molecular and cellular dissection of NMDA receptor subtypes as antidepressant targets. Neuroscience and Biobehavioral Reviews, 1-7. doi:10.1016/j.neubiorev.2017.08.012.

Cite as: https://hdl.handle.net/11858/00-001M-0000-002D-DB91-C

Abstract

A growing body of evidence supports the idea that drugs targeting the glutamate system may represent a valuable therapeutic alternative in major depressive disorders (MDD). The rapid and prolonged mood elevating effect of the NMDA receptor (NMDAR) antagonist ketamine has been studied intensely. However, its clinical use is hampered by deleterious side-effects, such as psychosis. Therefore, a better understanding of the mechanisms of the psychotropic effects after NMDAR blockade is necessary to develop glutamatergic antidepressants with improved therapeutic profile. Here we review recent experimental data that addressed molecular/cellular determinants of the antidepressant effect mediated by inactivating NMDAR subtypes. We refer to results obtained both in pharmacological and genetic animal models, ranging from global to conditional NMDAR manipulation. Our main focus is on the contribution of different NMDAR subtypes to the psychoactive effects induced by NMDAR ablation/blockade. We review data analyzing the effect of NMDAR subtype deletions limited to specific neuronal populations/brain areas in the regulation of mood. Altogether, these studies suggest effective and putative specific NMDAR drug targets for MDD treatment.